Affinia Therapeutics appoints Rami Daoud as CFO in Waltham, Sept 2024

Affinia Therapeutics has appointed Rami Daoud as Chief Business and Financial Officer, effective September 2024. Daoud is an industry veteran with over 25 years of experience in business development, corporate finance, and strategy within leading biopharmaceutical organizations. His previous roles include significant positions at Amarin Corporation and GeneSciences Pharmaceuticals, where he demonstrated expertise in deal-making and strategic initiatives across various global markets. Rick Modi, the CEO of Affinia, expressed enthusiasm about Daoud's appointment, highlighting his successful track record in the biopharma sector. Daoud's extensive background in therapeutic areas and commercialization models is expected to be instrumental as Affinia advances its innovative gene therapy platform, which targets cardiovascular and neurological diseases. Daoud holds an M.B.A. from the Wharton School and has degrees in physiology, accounting, and biology from the University of Maryland. His career began as a research scientist at the National Institutes of Health before transitioning to the biopharmaceutical industry. This diverse experience positions him well to contribute to Affinia's strategic priorities and help address high unmet medical needs in the healthcare sector. The appointment comes at a crucial time for Affinia, as the company aims to pioneer a new class of rationally-designed gene therapies. With Daoud's leadership, the organization is poised to enhance its pipeline and make significant strides in the treatment of rare and prevalent diseases.